Has Taliha Yasin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,668 in general payments to Taliha Yasin, MD across 112 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Taliha Yasin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Taliha Yasin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Taliha Yasin, MD

Infectious Disease · Poway, CANPI 1912361767

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,189 and has fallen 75.2% since, to $295 in 2025.

$2,668in general payments, 2019–2025

Across 112 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Paratek Pharmaceuticals, Inc.$527
Merck$310
AbbVie$309
Shionogi Inc$301
Insmed, Inc.$286
Aimmune Therapeutics, Inc.$248
plus $687 from 9 others

What the payments were for

Food & beverage$2,55896%
Education$1104%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Paratek Pharmaceuticals, Inc.	24	$527
Merck	12	$310
AbbVie	13	$309
Shionogi Inc	13	$301
Insmed, Inc.	11	$286
Aimmune Therapeutics, Inc.	10	$248
Gilead	13	$227
Astellas Pharma US Inc	4	$163
Viiv Healthcare Company	4	$102
La Jolla Pharmaceutical Company	2	$59
Theratechnologies Inc.	2	$47
Melinta Therapeutics, LLC	1	$26
Ferring Pharmaceuticals Inc.	1	$23
Biomerieux Inc	1	$22
Nabriva Therapeutics, PLC	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NUZYRA$125

How this compares

$2,668 in reported general payments places this provider in the 75th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California →

Medicare billing

Part B allowed, 2024

$116,255

Medicare patients

297

Services billed

855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Daptomycin	27	$23,994
Rifabutin	17	$11,386
CeftriaxoneCeftriaxone Sodium	27	$2,897
Cefazolin Sodium	45	$2,159
Moxifloxacin Hcl	17	$1,464
Methenamine Hippurate	13	$1,109
Rifampin	24	$1,064
Sodium Chloride0.9 % Sodium Chloride	13	$993
Cephalexin	26	$953
Ethambutol Hcl	17	$854
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	23	$601
Fluconazole	11	$532
Amoxicillin	15	$190
Levofloxacin	13	$107
Isoniazid	14	$87

Paid to pharmacies, not to this prescriber.

Other infectious disease in Poway

Claire PomeroySacramento$2.6M
Javeed SiddiquiRoseville$1.5M
George SakoulasSan Diego$902K
Arthur JengSylmar$766K
James McKinnellTorrance$762K
Jay GladsteinLos Angeles$657K
Tulika SinghOrange$654K
Otto YangLos Angeles$472K
Franco FelizartaBakersfield$440K
Shawn HasslerSan Francisco$433K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →